Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study

Open access
Connolly, Roisin M., Li, Huili, Jankowitz, Rachel C., Zhang, Zhe, Rudek, Michelle A., Jeter, Stacie C., Slater, Shannon A., Powers, Penny, Wolff, Antonio C., Fetting, John H., Brufsky, Adam, Piekarz, Richard, Ahuja, Nita, Laird, Peter W., Shen, Hui, Weisenberger, Daniel J., Cope, Leslie, Herman, James G., Somlo, George, Garcia, Agustin A., Jones, Peter A., Baylin, Stephen B., Davidson, Nancy E., Zahnow, Cynthia A., Stearns, Vered · 2017 · Clinical Cancer Research

Abstract

Purpose: In breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor led to reexpression of genes encoding important therapeutic targets, including the estrogen receptor (ER). We conducted a multicenter phase II study of 5-azacitidine and entinostat in women with advanced hormone-resistant or triple-negative breast cancer (TNBC). Experimental Design: Patients received 5-azacitidine 40 mg/m2 (days 1–5, 8–10) and entinostat 7 mg (days 3, 10) on a 28-day cycle. Continuation of epigenetic therapy was offered with the addition of endocrine therapy at the time of progression [optional continuation (OC) phase]. Primary endpoint was objective response rate (ORR) in each cohort. We hypothesized that ORR would be ≥20% against null of 5% using Simon two-stage design. At least one response was required in 1 of 13 patients per cohort to continue accrual to 27 per cohort (type I error, 4%; power, 90%). Results: There was one partial response among 27 women with hormone-resistant disease (ORR = 4%; 95% CI, 0–19), and none in 13 women with TNBC. One additional partial response was observed in the OC phase in the hormone-resistant cohort (n = 12). Mandatory tumor samples were obtained pre- and posttreatment (58% paired) with either up- or downregulation of ER observed in approximately 50% of posttreatment biopsies in the hormone-resistant, but not TNBC cohort. Conclusions: Combination epigenetic therapy was well tolerated, but our primary endpoint was not met. OC phase results suggest that some women benefit from epigenetic therapy and/or reintroduction of endocrine therapy beyond progression, but further study is needed. Clin Cancer Res; 23(11); 2691–701. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1729

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 162

Metadata

Authors
Connolly, R. M., Li, H., Jankowitz, R. C., Zhang, Z., Rudek, M. A., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., Brufsky, A., Piekarz, R., Ahuja, N., Laird, P. W., Shen, H., Weisenberger, D. J., Cope, L., Herman, J. G., Somlo, G., Garcia, A. A., Jones, P. A., Baylin, S. B., Davidson, N. E., Zahnow, C. A., & Stearns, V.
Venue
Clinical Cancer Research
Published
2017-05-31
Volume
23
Issue
11
Pages
2691-2701
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2564435391
Cited by
162
References
10
FWCI
5.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1729
The paper
Connolly, R. M., Li, H., Jankowitz, R. C., Zhang, Z., Rudek, M. A., Jeter, S. C., Slater, S. A., Powers, P., Wolff, A. C., Fetting, J. H., Brufsky, A., Piekarz, R., Ahuja, N., Laird, P. W., Shen, H., Weisenberger, D. J., Cope, L., Herman, J. G., Somlo, G., . . . Stearns, V. (2017). Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.